Acknowledgement

We would like to thank:

• The Bristol Urological Institute and

• The Urology Department at La Pitié Hospital in Paris and its chairman Professor F. Richard

for kindly providing logistic assistance for the editing of this book.

We would also like to thank all the contributors for their enthusiastic support and help.

For information and orders:

Distributor: EDITIONS 21
76, rue de la Pompe - 75016 Paris - FRANCE
Fax: +33 1 45 04 72 89  E-mail: editions21@wanadoo.fr

© Health Publication Ltd 2009

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission of the publisher.

Accurate indications, adverse reactions, and dosage schedules for drugs are provided in this book, but it is possible that they may change. The reader is urged to review the package information data of the manufacturers of the medications mentioned.

The Publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The great tragedy of science:
The slaying of a beautiful hypothesis by an ugly fact
Thomas Huxley (1825-1895)

ISBN  0-9546956-8-2

LAY-OUT: Stéphanie Taïeb
FOREWORD

The First International Consultation on Incontinence held in 1998 highlighted the plight of some 200 millions sufferers from urinary incontinence worldwide. Urinary incontinence represents a particular and severe problem in certain developing areas of the world, where labour and birth injuries lead to catastrophic leakage. Untreated vesico-vaginal fistula (VVF), particularly in sub Saharan Africa, affects millions of women causing ostracism from society. Because of the enormity of this particular problem, at the second consultation we added a specific committee to highlight the subject, to advance the understanding of the causes of birth injury, to lead to improved treatment for the many untreated women, and most importantly, to begin preventative programmes. At this Fourth Consultation we were delighted by the active participation of the WHO in our work on VVF.

There were two other new committees in the 2nd ICI: Pelvic Organ Prolapse and Faecal Incontinence. The first consultation stressed the importance of a multidisciplinary approach to continence care, and the new committees on pelvic organ prolapse and faecal incontinence recognize that, particularly in women, urinary incontinence coexists with prolapse and faecal incontinence in many instances. This is also true, to a more limited extent, in men with coexisting faecal incontinence. The task of these two committees was very considerable and they had to outline the basic science, and investigation and management techniques within a single chapter. The report of these two chapters laid the foundation for a broadening of the multidisciplinary approach to pelvic disorders which was further developed in the 3rd ICI and now in the 4th ICI. New patterns by which care is delivered are emerging and depend on the close collaboration between urologists, gynaecologists and coloproctologists, working within a multidisciplinary team with nurses and physiotherapists. From the research and investigation point of view, we are very dependent on our colleagues from other disciplines such as the basic sciences, epidemiology, social science and engineering.

The 4th Consultation on Incontinence was held in Paris in July 2008. In this consultation we gave a special attention the VV fistula in the developing world in collaboration with the WHO and many other associations working in this field. The structure of the consultation followed the successful formula developed by the ICUD and used for the previous 3 consultations. Once again an international faculty of over 150 individuals from a wide range of professions and specialities were grouped into a series of subcommittees, each with a specific area of responsibility. The spectrum of subcommittees spanned from Basic Science through assessment and investigation to therapy. These committees were further divided into specific patient groups for children, women, men, neurological patients and the frail elderly. In addition to fully integrating faecal incontinence and pelvic organ prolapse into the consultation, there was the renamed committee “Bladder Pain Syndrome”.

Subcommittee members were selected according to their academic reputation giving due recognition to the need to provide balance between specialities and geographical regions. A chairperson was selected for each subcommittee and was responsible for the drafting of that committees’ chapter. Most committees met at least once before the consultation in Paris, to progress their report.

Each chairperson presented his or her committees’ main discussions and recommendations in Paris. Their chapter was then modified accordingly, in the light of the consultation. This book details the evidence reviewed by each committee. Each committee used the ICUD System for evaluating evidence and providing recommendations with five levels of evidence (1 to 5) and four grades of recommendation (A to D).

This system worked well for the treatment committees but, as yet, it cannot be applied systematically to evaluate the evidence from the basic science and investigation committees. Nevertheless, the consultation feels that continued efforts to specify the evidence base for all recommendations are of vital importance.

The book’s final chapter is the Recommendations of the International Scientific Committee which includes all subcommittee chairs together with the members of the Steering Committee. This chapter has been expanded to include algorithms for the treatment of faecal incontinence, pelvic organ prolapse and bladder pain syndrome. Furthermore, the 2004 algorithms have been reconfigured in the light of new evidence and in order to facilitate their use.

*These recommendations represent the evidence based opinion of a group of experts. They are not to be considered as guidelines or standards of care which are the responsibility of official organisations, governments and regulators.*

We hope that the huge amount of effort put into the consultation and the production of this book will also be reflected in an increased prominence for all aspects of the consultation’s findings. We shall make the book more widely available and publish sections of the book in peer reviewed journals.

Paul Abrams and the Scientific Committee
Some of the members of the International
Committees Paris, France - July 5-8, 2008
MEMBERS OF THE COMMITTEES
(Alphabetical order - Chairmen in bold print)
<table>
<thead>
<tr>
<th></th>
<th>Name</th>
<th>Country</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>KELLEHER</td>
<td>Con</td>
<td>UK</td>
</tr>
<tr>
<td>7</td>
<td>KHULLAR</td>
<td>Vik</td>
<td>UK</td>
</tr>
<tr>
<td>13</td>
<td>KIRSCHNER-HERMANNS</td>
<td>Ruth</td>
<td>Germany</td>
</tr>
<tr>
<td>7</td>
<td>KLUIVERS</td>
<td>K</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>4</td>
<td>KOEUBL</td>
<td>Heinz</td>
<td>Germany</td>
</tr>
<tr>
<td>5</td>
<td>KOPP</td>
<td>Z.</td>
<td>USA</td>
</tr>
<tr>
<td>10</td>
<td>KOVINDHA</td>
<td>Apichana</td>
<td>Thailand</td>
</tr>
<tr>
<td>11</td>
<td>KUCHEL</td>
<td>George A.</td>
<td>USA</td>
</tr>
<tr>
<td>23</td>
<td>KUSEK</td>
<td>John</td>
<td>USA</td>
</tr>
<tr>
<td>16</td>
<td>LANG</td>
<td>Julie</td>
<td>UK</td>
</tr>
<tr>
<td>1</td>
<td>LAPITAN</td>
<td>Marie Carmela</td>
<td>Philippines</td>
</tr>
<tr>
<td>17</td>
<td>LAURBERG</td>
<td>Soren</td>
<td>Denmark</td>
</tr>
<tr>
<td>19</td>
<td>LIN</td>
<td>Alex Tong-Long</td>
<td>Taiwan</td>
</tr>
<tr>
<td>10</td>
<td>MADERSBACHER</td>
<td>Helmut</td>
<td>Austria</td>
</tr>
<tr>
<td>17</td>
<td>MADOFF</td>
<td>Robert</td>
<td>USA</td>
</tr>
<tr>
<td>15</td>
<td>MAHER</td>
<td>Christopher</td>
<td>Australia</td>
</tr>
<tr>
<td>17</td>
<td>MATZEL</td>
<td>A.</td>
<td>Germany</td>
</tr>
<tr>
<td>3</td>
<td>MAYER</td>
<td>Emeran</td>
<td>USA</td>
</tr>
<tr>
<td>15</td>
<td>MELGREM</td>
<td>A.</td>
<td>USA</td>
</tr>
<tr>
<td>17</td>
<td>MELLGREN</td>
<td>Anders</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>8</td>
<td>MICHEL</td>
<td>Martin</td>
<td>UK</td>
</tr>
<tr>
<td>3</td>
<td>MILLS</td>
<td>Ian</td>
<td>Sweden</td>
</tr>
<tr>
<td>1</td>
<td>MILSOM</td>
<td>Ian</td>
<td>Japan</td>
</tr>
<tr>
<td>17</td>
<td>MIMURA</td>
<td>Toshiki</td>
<td>Canada</td>
</tr>
<tr>
<td>12</td>
<td>MOORE</td>
<td>Katherine</td>
<td>Australia</td>
</tr>
<tr>
<td>22</td>
<td>MOORE</td>
<td>John</td>
<td>U A Emirates</td>
</tr>
<tr>
<td>12</td>
<td>N'DOW</td>
<td>James</td>
<td>UK</td>
</tr>
<tr>
<td>1</td>
<td>NELSON</td>
<td>Richard</td>
<td>U.K.</td>
</tr>
<tr>
<td>21</td>
<td>NEWMAN</td>
<td>Diane</td>
<td>USA</td>
</tr>
<tr>
<td>9</td>
<td>NUMAN</td>
<td>Rien</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>14</td>
<td>NILSSON</td>
<td>Karl Gustav</td>
<td>Finland</td>
</tr>
<tr>
<td>21</td>
<td>NISHIMURA</td>
<td>Koaru</td>
<td>Japan</td>
</tr>
<tr>
<td>4</td>
<td>NITTI</td>
<td>Victor</td>
<td>USA</td>
</tr>
<tr>
<td>19</td>
<td>NORDLING</td>
<td>Jorgen</td>
<td>Denmark</td>
</tr>
<tr>
<td>15</td>
<td>NORTON</td>
<td>Peggy</td>
<td>USA</td>
</tr>
<tr>
<td>16</td>
<td>NORTON</td>
<td>Christine</td>
<td>USA</td>
</tr>
<tr>
<td>21</td>
<td>NORTON</td>
<td>Nancy</td>
<td>USA</td>
</tr>
<tr>
<td>19</td>
<td>NYBERG</td>
<td>Leroy</td>
<td>USA</td>
</tr>
<tr>
<td>12</td>
<td>NYGAARD</td>
<td>Ingrid</td>
<td>USA</td>
</tr>
<tr>
<td>17</td>
<td>OCONNELL</td>
<td>Ronan</td>
<td>IRLAND</td>
</tr>
<tr>
<td>11</td>
<td>PALMER</td>
<td>Mary</td>
<td>USA</td>
</tr>
<tr>
<td>20</td>
<td>PATERSON</td>
<td>Jan</td>
<td>Australia</td>
</tr>
<tr>
<td>3</td>
<td>PATON</td>
<td>Julian</td>
<td>UK</td>
</tr>
<tr>
<td>23</td>
<td>PAYNE</td>
<td>Chris</td>
<td>USA</td>
</tr>
<tr>
<td>19</td>
<td>PAYNE</td>
<td>Chris</td>
<td>USA</td>
</tr>
<tr>
<td>10</td>
<td>PERKASH</td>
<td>I.</td>
<td>USA</td>
</tr>
<tr>
<td>11</td>
<td>PFISTERER</td>
<td>Mathias</td>
<td>Germany</td>
</tr>
<tr>
<td>20</td>
<td>PIETERS</td>
<td>Ronny</td>
<td>Belgium</td>
</tr>
<tr>
<td>7</td>
<td>PODNAR</td>
<td>S.</td>
<td>Slovenia</td>
</tr>
<tr>
<td>10</td>
<td>RADZISZEWSKI</td>
<td>Piotr</td>
<td>Poland</td>
</tr>
<tr>
<td>15</td>
<td>RAJAMAHESWARI N.</td>
<td>India</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>RATNER</td>
<td>Vicki</td>
<td>USA</td>
</tr>
<tr>
<td>6</td>
<td>ROBAIN</td>
<td>Gilberte</td>
<td>France</td>
</tr>
<tr>
<td>2</td>
<td>ROOSEN</td>
<td>A.</td>
<td>Germany</td>
</tr>
<tr>
<td>23</td>
<td>RORTVEIT</td>
<td>Guri</td>
<td>Norway</td>
</tr>
<tr>
<td>6</td>
<td>ROSIER</td>
<td>Peter</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>14</td>
<td>ROVNER</td>
<td>Eric</td>
<td>USA</td>
</tr>
<tr>
<td>10</td>
<td>RUFFION</td>
<td>Alain</td>
<td>France</td>
</tr>
<tr>
<td>10</td>
<td>SAKAKIBARA</td>
<td>Ryuji</td>
<td>Japan</td>
</tr>
<tr>
<td>4</td>
<td>SALVATORE</td>
<td>Stefano</td>
<td>Italy</td>
</tr>
<tr>
<td>6</td>
<td>SAND</td>
<td>Peter K</td>
<td>USA</td>
</tr>
<tr>
<td>10</td>
<td>SCHURCH</td>
<td>Brigitte</td>
<td>Switzerland</td>
</tr>
<tr>
<td>1</td>
<td>SILLEN</td>
<td>Ulla</td>
<td>Sweden</td>
</tr>
<tr>
<td>18</td>
<td>SINGH</td>
<td>P.B.</td>
<td>India</td>
</tr>
<tr>
<td>14</td>
<td>SMITH</td>
<td>Tony</td>
<td>UK</td>
</tr>
<tr>
<td>18</td>
<td>SOMBIE</td>
<td>Issiaka</td>
<td>Burkina Faso</td>
</tr>
<tr>
<td>21</td>
<td>SRINI</td>
<td>Vasan Satya</td>
<td>India</td>
</tr>
<tr>
<td>5</td>
<td>STASKIN</td>
<td>David</td>
<td>USA</td>
</tr>
<tr>
<td>2</td>
<td>STEERS</td>
<td>William</td>
<td>USA</td>
</tr>
<tr>
<td>23</td>
<td>STOTHERS</td>
<td>Mary-Ann Lynn</td>
<td>Canada</td>
</tr>
<tr>
<td>22</td>
<td>SUBAK</td>
<td>Ieslee</td>
<td>USA</td>
</tr>
<tr>
<td>4</td>
<td>SULTAN</td>
<td>Abdul</td>
<td>UK</td>
</tr>
<tr>
<td>6</td>
<td>SZABO</td>
<td>Laszlo</td>
<td>Hungary</td>
</tr>
<tr>
<td>2</td>
<td>TAKEDA</td>
<td>Masayuki</td>
<td>Japan</td>
</tr>
<tr>
<td>8</td>
<td>TANNENBAUM</td>
<td>Cara</td>
<td>Canada</td>
</tr>
<tr>
<td>9</td>
<td>TEKGUL</td>
<td>Serdar</td>
<td>Turkey</td>
</tr>
<tr>
<td>1</td>
<td>THOM</td>
<td>David H.</td>
<td>USA</td>
</tr>
<tr>
<td>3</td>
<td>THOR</td>
<td>Karl</td>
<td>USA</td>
</tr>
<tr>
<td>7</td>
<td>TUBARO</td>
<td>Andrea</td>
<td>Italy</td>
</tr>
<tr>
<td>19</td>
<td>UEDA</td>
<td>Tomohiro</td>
<td>Japon</td>
</tr>
<tr>
<td>23</td>
<td>VAN KERREBORECK Philip</td>
<td>Philip</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>19</td>
<td>VAN OPHOREN</td>
<td>Arndt</td>
<td>Germany</td>
</tr>
<tr>
<td>17</td>
<td>VARMA</td>
<td>Mika</td>
<td>USA</td>
</tr>
<tr>
<td>7</td>
<td>VIERHOUT</td>
<td>M.E.</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>7</td>
<td>VODUSEK</td>
<td>David</td>
<td>Slovenia</td>
</tr>
<tr>
<td>9</td>
<td>VON GONTHARD</td>
<td>Alexander</td>
<td>Germany</td>
</tr>
<tr>
<td>15</td>
<td>VON THEOBALD</td>
<td>Peter</td>
<td>France</td>
</tr>
<tr>
<td>11</td>
<td>WAGG</td>
<td>Adrian</td>
<td>UK</td>
</tr>
<tr>
<td>22</td>
<td>WAGNER</td>
<td>Todd</td>
<td>USA</td>
</tr>
<tr>
<td>18</td>
<td>WALL</td>
<td>Lewis</td>
<td>USA</td>
</tr>
<tr>
<td>15</td>
<td>WANG</td>
<td>Alex</td>
<td>Taiwan</td>
</tr>
<tr>
<td>8</td>
<td>WEIN</td>
<td>Alan</td>
<td>USA</td>
</tr>
<tr>
<td>16</td>
<td>WHITEHEAD</td>
<td>William</td>
<td>USA</td>
</tr>
<tr>
<td>20</td>
<td>WILDE</td>
<td>Mary</td>
<td>USA</td>
</tr>
<tr>
<td>21</td>
<td>WILLIAMS</td>
<td>Kate</td>
<td>UK</td>
</tr>
<tr>
<td>2</td>
<td>WOOD</td>
<td>Dan</td>
<td>UK</td>
</tr>
<tr>
<td>10</td>
<td>WYNDAELE</td>
<td>Jean Jacques</td>
<td>Belgium</td>
</tr>
<tr>
<td>4</td>
<td>YAMAGUCHI</td>
<td>Osamu</td>
<td>Japan</td>
</tr>
<tr>
<td>5</td>
<td>YOSHIDA</td>
<td>Masaki</td>
<td>Japan</td>
</tr>
<tr>
<td>23</td>
<td>ZIMMERN</td>
<td>Philippe</td>
<td>USA</td>
</tr>
</tbody>
</table>
## Members of the Committees (by Committee)

### 1. Epidemiology
- **ALTMAN** Daniel Sweden
- **HERBISON** Peter New Zealand
- **LAPITAN** Marie C. Philippines
- **MILSOM** Ian Sweden
- **NELSON** Richard U.K.
- **SILLEN** Ulla Sweden
- **THOM** David H. USA

### 2. Cell Biology
- **FRY** Chris UK
- **KANAI** Tony USA
- **STEERS** William USA
- **TAKEDA** Masayuki Japan
- **ROOSEN** A. Germany
- **TAKEDA** Masayuki Japan
- **WOOD** Dan UK

### 3. Neural Control
- **BIRDER** Lori USA
- **DE GROAT** Chet USA
- **DRAKE** Marcus UK
- **FOWLER** Clare UK
- **GRIFFITHS** Derek USA
- **MAYER** Emeran USA
- **MILLS** Ian UK
- **MORRISON** John Arab Emirates
- **PATON** Julian UK
- **THOR** Karl USA

### 4. Pathophysiology
- **BAESSLER** Kaven Germany
- **BOURCIER** Alain France
- **KARRAM** Mickey U.K.
- **KOELBL** Heinz Germany
- **NITTI** Victor USA
- **SALVATORE** Stefano Italy
- **SULTAN** Abdul UK
- **YAMAGUCHI** Osamu Japan

### 5. Initial Assessment Including Quality of Life
- **avery** Kerry UK
- **BOSCH** Ruud The Netherlands
- **COTTERILL** Nikki UK
- **COYNE** Karen USA
- **EMMANUEL** Anton UK
- **HIRSCH** Mark USA
- **KELLEHER** Con UK
- **KOPP** Z. USA
- **STASKIN** David USA
- **YOSHIIDA** Masaki Japan

### 6. Dynamic Testing
- **CAPEWELL** Ann UK
- **GAJEWSKI** Jerzy Canada
- **HOSKER** Gordon UK
- **ROBAIN** Gilberte France
- **ROSIER** Peter The Netherlands
- **SAND** Peter K USA
- **SZABO** Laszlo Hungary

### 7. Imaging, Neurophysiology and other Tests
- **AMARENCO** Gerard France
- **ARTIBANI** Walter Italy
- **BARTRAM** Clive UK
- **DE GENNARO** M. Italy
- **DELANCEY** John USA
- **KHULLAR** Vik UK
- **KLIVERS** K The Netherlands
- **PODNAR** S. Slovenia
- **TUBARO** Andrea Italy
- **VIERHOUT** M.E. The Netherlands
- **VODUSEK** David Slovenia

### 8. Drug Treatment
- **ANDERSSON** Karl Eric Sweden
- **CARDOZO** Linda UK
- **CHAPPLE** Chris UK
- **CRUZ** Francisco Portugal
- **HAMPHEL** Christian Germany
- **HASHIM** H. U.K.
- **MICHEL** Martin The Netherlands
- **TANNENBAUM** Cara Canada
- **WEIN** Alan USA

### 9. Children
- **BOWER** Wendy Hong Kong
- **CANNING** Dough USA
- **HOEBEKE** Piet Belgium
- **NIJMAN** Rien The Netherlands
- **TEKGUL** Serdar Turkey
- **VON GONTARD** Alexander Germany

### 10. Neurogenic Patients
- **CASTRO** David Spain
- **IGAWA** Yasuhiro Japan
- **KOVINDHA** Apichana Thailand
- **MADERSBACHER** Helmut Austria
- **PERKASH** I. USA
- **RADZIJEWSKI** Piotr Poland
- **RUFTION** Alain France
- **SAKAKIBARA** Ryuji Japan
- **SCHURCH** Brigitte Switzerland
- **WYNDMELE** J-Jacques Belgium

### 11. Frail Elderly
- **DUBEAU** Catherine USA
- **HARARI** Danielle UK
- **JOHNSON** Ted USA
- **KUCHEL** George A. USA
- **PALMER** Mary USA
- **PFISTERER** Mathias Germany
- **WAGG** Adrian UK
12. Adult Conservative Management
BERGHMANS Bary, The Netherlands
BURGIO Kathryn, USA
DUMOULIN Chantale, Canada
HAGEN Suzanne, UK
HAY SMITH Jean, New Zealand
MOORE Katherine, Canada
N’DOW James, UK
NYGAARD Ingrid, USA

13. Surgery for Urinary Incontinence in Men
BRUSCHINI Homero, Brazil
COMITER Craig, USA
COUR Florence, France
GRISE Philippe, France
HANUS Tomas, Czech Republic
HERSCHORN Sender, Canada
KIRSCHNER-HERMANNS Ruth, Germany

14. Surgery for Urinary Incontinence in Women
CHANG Debuene, USA
CHARTIER KASTLER Emmanuel, France
DMOCHOWSKI Roger, USA
HILTON Paul, UK
NILSSON Karl Gustav, Finland
ROVNER Eric, USA
SMITH Tony, UK

15. Surgery for Pelvic Organ Prolapse
BRUBAKER Linda, USA
GLAZENER Charis, U.K
JACQUETIN Bernard, France
MAHER Christopher, Australia
MELGREM A., USA
NORTON Peggy, USA
RAJAMAHESWARI N., India
VON THEOBALD Peter, France
WANG Alex, Taiwan

16. Conservative Treatment for Faecal Incontinence
BLISS Donna Z., USA
HARARI Danielle, UK
LANG Julie, UK
NORTON Christine, UK
WHITEHEAD William, USA

17. Surgery for Faecal Incontinence
LAURBERG Soren, Denmark
MADOFF Robert, USA
MATZEL Klaus, Germany
MELGREM_A., USA
MIMURA Toshiki, Japan
O’CONNELL Ronan, Ireland
VARMA Mika, USA

18. Vesico-Vaginal Fistulas in the Developing World
BADLANI gopal, USA
BROWNING Andrew, Ethiopia
DE RIDDER Dirk, Belgium
SINGH P.B., India
SOMBIE Issiaka, Burkina Faso
WALL Lewis, USA

19. Painful Bladder Syndrome
HANNO Philip, USA
LIN A.Tong-Jung, Taiwan
NORDLING Jorgen, Denmark
NYBERG Leroy, USA
PAYNE Chris, USA
RATNER Vicki, USA
UEDA Tomohiro, Japon
VAN OPHOREN Arndt, Germany

20. Technical Aspects of Continence Devices
BLISS Donna Z., USA
BUCKLEY Brian, Ireland
COTTENDEN Alan, UK
FAKER Mandy, UK
GETLIFE Katheryne, UK
PATERSON Jan, Australia
PIETERS Ronny, Belgium
WILDE Mary, USA

21. Education and Continence Promotion
CAHILL Barry, Australia
EE Chyehua, Singapore
GORDON Deborah, Australia
GORDON T., USA
NEWMAN Diane, USA
NISHIMURA Kaoru, Japan
NORTON Nancy, USA
SRINI Vasan Satya, India
WILLIAMS Kate, UK

22. Economics of Incontinence
DEUTEKOM Marije, The Netherlands
HAWTHORNE Graeme, Australia
HU Teh-Wei, USA
MOORE Kate, Australia
SUBAK leslee, USA
WAGNER Todd, USA

23. Research
BROWN Jeanette, USA
CASTRO David, Spain
DANESGHARIR Firouz, USA
HAAB Francois, France
IGAWA Yasuhiko, Japan
KUSEK John, USA
PAYNE Chris, USA
RORTVEIT Guri, Norway
STOTHERS Mary-Ann L., Canada
VAN KERREBOECK Philip, The Netherlands
ZIMMERN Philippe, USA
Dr. William C. de Groat is Professor of Pharmacology at the University of Pittsburgh Medical School. He received a Ph.D. in Pharmacology from the University of Pennsylvania Medical School in 1965 and then obtained postdoctoral training in Pharmacology at the University of Pennsylvania (1965-1966) and in Neurophysiology at the John Curtin School for Medical Research in Canberra, Australia (1966-1968).

He joined the faculty at the University of Pittsburgh in 1968 and was promoted to Professor in 1977. He has been a Visiting Scientist at the NIH (1988-1989) and at the University College London (1998).

He is an Honorary Member of the American Urological Association and the Japanese Urological Association. Dr. de Groat has published more than 400 papers primarily in the fields of autonomic neuroscience and neurourology. He has served on numerous editorial boards including: *The Journal of Pharmacology and Experimental Therapeutics, American Journal of Physiology, Urology, Neurourology and Urodynamics, Autonomic Neuroscience, and Life Sciences.*

Dr. de Groat has been Treasurer and a member of the Executive Council of the Society for Neuroscience and the Executive Vice President of the International Society for Autonomic Neuroscience. He is the recipient of a number of awards including: a National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) Award, an NIH Research Career Development Award, a Lifetime Achievement Award from the Urodynamics Society and a Fellow of the American Association for Advancement of Science.

He has been recognized with the Carl Ludwig Distinguished Lectureship of the American Physiological Society, the University of Pittsburgh President’s Distinguished Research Award, the Pharmacia-ASPET Award for Experimental Therapeutics from the American Society for Pharmacology and Experimental Therapeutics, the Elsevier-JANS Lectureship of the International Society for Autonomic Neuroscience, the Sir Ludwig Guttman Lectureship of the International Society of Paraplegia and the University of Pittsburgh Chancellor’s Distinguished Teaching Award.

**SYNOPSIS OF AREA OF INTEREST:** Dr. de Groat is interested in the neural control of the lower urinary tract and the mechanisms underlying urinary incontinence and painful bladder conditions.
EVIDENCE – BASED MEDICINE OVERVIEW OF THE MAIN STEPS FOR DEVELOPING AND GRADING GUIDELINE RECOMMENDATIONS.

INTRODUCTION
The International Consultation on Urological Diseases (ICUD) is a non-governmental organization registered with the World Health Organisation (WHO). In the last ten years Consultations have been organised on BPH, Prostate Cancer, Urinary Stone Disease, Nosocomial Infections, Erectile Dysfunction and Urinary Incontinence. These consultations have looked at published evidence and produced recommendations at four levels; highly recommended, recommended, optional and not recommended. This method has been useful but the ICUD believes that there should be more explicit statements of the levels of evidence that generate the subsequent grades of recommendations.

The Agency for Health Care Policy and Research (AHCPR) have used specified evidence levels to justify recommendations for the investigation and treatment of a variety of conditions. The Oxford Centre for Evidence Based Medicine have produced a widely accepted adaptation of the work of AHCPR. (June 5th 2001 http://minerva.minervation.com/cebm/docs/levels.html)

The ICUD has examined the Oxford guidelines and discussed with the Oxford group their applicability to the Consultations organised by ICUD. It is highly desirable that the recommendations made by the Consultations follow an accepted grading system supported by explicit levels of evidence.

The ICUD proposes that future consultations should use a modified version of the Oxford system which can be directly ’mapped’ onto the Oxford system.

1. 1st Step: Define the specific questions or statements that the recommendations are supposed to address.

2. 2nd Step: Analyse and rate (level of evidence) the relevant papers published in the literature.

   The analysis of the literature is an important step in preparing recommendations and their guarantee of quality.

2.1 What papers should be included in the analysis?

   • Papers published, or accepted for publication in the peer reviewed issues of journals.
   • The committee should do its best to search for papers accepted for publication by the peer reviewed journals in the relevant field but not yet published.
   • Abstracts published in peer review journals should be identified. If of sufficient interest the author(s) should be asked for full details of methodology and results. The relevant committee members can then ‘peer review’ the data, and if the data confirms the details in the abstract, then that abstract may be included, with an explanatory footnote. This is a complex issue – it may actually increase publication bias as “uninteresting” abstracts commonly do not progress to full publication.
   • Papers published in non peer reviewed supplements will not be included.

An exhaustive list should be obtained through:

I. the major databases covering the last ten years (e.g. Medline, Embase, Cochrane Library, Biosis, Science Citation Index)

II. the table of contents of the major journals of urology and other relevant journals, for the last three months, to take into account the possible delay in the indexation of the published papers in the databases.

It is expected that the highly experienced and expert committee members provide additional assurance that no important study would be missed using this review process.

2.2 How papers are analysed?

   Papers published in peer reviewed journals have differing quality and level of evidence.

   Each committee will rate the included papers according to levels of evidence (see below).

   The level (strength) of evidence provided by an individual study depends on the ability of the study design to minimise the possibility of bias and to maximise attribution.

   is influenced by:

   • the type of study
   • how well the study was designed and carried out

   Failure to give due attention to key aspects of study methodology increase the risk of bias or confounding factors, and thus reduces the study’s reliability.

   The use of standard check lists is recommended to insure that all relevant aspects are considered and that a consistent approach is used in the methodological assessment of the evidence.

   The objective of the check list is to give a quality rating for individual studies.

   • how well the study was reported
   • how well the study was rated

   The ICUD has adopted the CONSORT statement and its widely accepted check list. The CONSORT statement and the checklist are available at: http://www.consort-statement.org

2.3 How papers are rated?

   Papers are rated following a ‘Level of Evidence scale’.

   ICUD has modified the Oxford Center for Evidence-Based Medicine levels of evidence.

   The levels of evidence scales vary between types of studies (ie therapy, diagnosis, differential diagnosis/symptom prevalence study).

   The Oxford Center for Evidence-Based Medicine Website: http://minerva.minervation.com/cebm/docs/levels.html

3. 3rd Step: Synthesis of the evidence

   After the selection of the papers and the rating of the level of evidence of each study, the next step is to compile a summary of the individual studies and the overall direction of the evidence in an Evidence Table.

4. 4th Step: Considered judgment (Integration of individual clinical expertise)

   Having completed a rigorous and objective synthesis of the evidence base, the committee must then make a judgement as to the grade of the recommendation on the basis of this evidence. This requires the exercise of judgement based on clinical experience as well as knowledge of the evidence and the methods used to generate it. Evidence based medicine requires the integration of individual clinical expertise with best available external clinical evidence from systematic research.

   Without the former, practice quickly becomes tyrannised by evidence, for even excellent external evidence may be inapplicable to, or inappropriate for, an individual patient:

   without current best evidence, practice quickly becomes out of date. Although it is not practical to lay our “rules”
for exercising judgement, guideline development groups are asked to consider the evidence in terms of quantity, quality, and consistency; applicability; generalisability; and clinical impact.

5. 5th Step: Final Grading
The grading of the recommendation is intended to strike an appropriate balance between incorporating the complexity of type and quality of the evidence and maintaining clarity for guideline users.

The recommendations for grading follow the Oxford Centre for Evidence-Based Medicine.

The levels of evidence shown below have again been modified in the light of previous consultations. There are now 4 levels of evidence instead of 5.

The grades of recommendation have not been reduced and a “no recommendation possible” grade has been added.

6. Levels of Evidence and Grades of Recommendation

6.1 Levels of Evidence

Firstly, it should be stated that any level of evidence may be positive (the therapy works) or negative (the therapy doesn’t work). A level of evidence is given to each individual study.

- **Level 1** evidence (incorporates Oxford 1a, 1b) usually involves meta-analysis of trials (RCTs) or a good quality randomised controlled trial, or ‘all or none’ studies in which no treatment is not an option, for example in vesicovaginal fistula.

- **Level 2** evidence (incorporates Oxford 2a, 2b and 2c) includes “low” quality RCT (e.g. < 80% follow up) or meta-analysis (with homogeneity) of good quality prospective ‘cohort studies’. These may include a single group when individuals who develop the condition are compared with others from within the original cohort group. There can be parallel cohorts, where those with the condition in the first group are compared with those in the second group.

- **Level 3** evidence (incorporates Oxford 3a, 3b and 4) includes:
  - good quality retrospective ‘case-control studies’ where a group of patients who have a condition are matched appropriately (e.g. for age, sex etc) with control individuals who do not have the condition.
  - good quality ‘case series’ where a complete group of patients all, with the same condition/disease/therapeutic intervention, are described, without a comparison control group.

- **Level 4** evidence (incorporates Oxford 4) includes expert opinion were the pinion is based not on evidence but on ‘first principles’ (e.g. physiological or anatomical) or bench research. The Delphi process can be used to give ‘expert opinion’ greater authority. In the Delphi process a series of questions are posed to a panel; the answers are collected into a series of ‘options’; the options are serially ranked; if a 75% agreement is reached then a Delphi consensus statement can be made.

6.2 Grades of Recommendation

The ICUD will use the four grades from the Oxford system. As with levels of evidence the grades of evidence may apply either positively (do the procedure) or negatively (don’t do the procedure). Where there is disparity of evidence, for example if there were three well conducted RCT’s indicating that Drug A was superior to placebo, but one RCT whose results show no difference, then there has to be an individual judgement as to the grade of recommendation given and the rationale explained.

- **Grade A** recommendation usually depends on consistent level 1 evidence and often means that the recommendation is effectively mandatory and placed within a clinical care pathway. However, there will be occasions where excellent evidence (level 1) does not lead to a Grade A recommendation, for example, if the therapy is prohibitively expensive, dangerous or unethical. Grade A recommendation can follow from Level 2 evidence. However, a Grade A recommendation needs a greater body of evidence if based on anything except Level 1 evidence

- **Grade B** recommendation usually depends on consistent level 2 and or 3 studies, or ‘majority evidence’ from RCT's

- **Grade C** recommendation usually depends on level 4 studies or ‘majority evidence’ from level 2/3 studies or Delphi processed expert opinion.

- **Grade D** “No recommendation possible” would be used where the evidence is inadequate or conflicting and when expert opinion is delivered without a formal analytical process, such as by Delphi.

7. Levels of Evidence and Grades of Recommendation for Methods of Assessment and Investigation

From initial discussions with the Oxford group it is clear that application of levels of evidence/grades of recommendation for diagnostic techniques is much more complex than for interventions. The ICUD recommend, that, as a minimum, any test should be subjected to three questions:

1. does the test have good technical performance, for example, do three aliquots of the same urine sample give the same result when subjected to ‘stix’ testing?
2. Does the test have good diagnostic performance, ideally against a “gold standard” measure?
3. Does the test have good therapeutic performance, that is, does the use of the test alter clinical management, does the use of the test improve outcome?

For the third component (therapeutic performance) the same approach can be used as for section 6.

8. Levels of Evidence and Grades of Recommendation for Basic Science and Epidemiology Studies

The proposed ICUD system does not easily fit into these areas of science. Further research needs to be carried out, in order to develop explicit levels of evidence that can lead to recommendations as to the soundness of data in these important aspects of medicine.

CONCLUSION

The ICUD believes that its consultations should follow the ICUD system of levels of evidence and grades of recommendation, where possible. This system can be mapped to the Oxford system.

There are aspects to the ICUD system that require further research and development, particularly diagnostic performance and cost effectiveness, and also factors such as patient preference.

P. Abrams, S Khoury, A. Grant 19/1/04
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FOREWORD</strong></td>
<td>3</td>
</tr>
<tr>
<td><strong>PRESIDENT</strong></td>
<td>10</td>
</tr>
<tr>
<td><strong>LEVELS OF EVIDENCE AND GRADES OF RECOMMENDATION</strong></td>
<td>12</td>
</tr>
<tr>
<td><strong>A Brief history of urinary incontinence and its treatment</strong></td>
<td>19</td>
</tr>
<tr>
<td>Dirk Schultheiss (Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 1</strong> : Epidemiology of Urinary (UI) and Faecal (FI) Incontinence and Pelvic Organ Prolapse (POP)</td>
<td>35</td>
</tr>
<tr>
<td>I. Milsom (Sweden) D. Altman (Sweden), M.C. Lapitan (The Philippines), R. Nelson (U.K), U. Sillén (Sweden), D. Thom (USA)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 2</strong> : Cell Biology</td>
<td>113</td>
</tr>
<tr>
<td>C.H Fry (U.K), A.J Kanai (USA), A. Roosen (Germany), M. Takeda (Japan), D.N Wood (U.K)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 3</strong> : Neural Control</td>
<td>167</td>
</tr>
<tr>
<td>L. Birder (USA), M. Drake (UK), W. de Groat (USA), C. Fowler (U.K), E. Mayer (USA), J. Morrison (UAE), J. Paton (U.K)</td>
<td></td>
</tr>
<tr>
<td>Consultants : D. Griffiths (Canada), I. Mills (U.K), K. Thor (USA)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 4</strong> : Pathophysiology of Urinary Incontinence, Faecal Incontinence and Pelvic Organ Prolapse</td>
<td>255</td>
</tr>
<tr>
<td>H. Koelbl (Germany) V. Nitti (USA), K. Baessler (Germany), S. Salvatore (Italy), A. Sultan (U.K), O. Yamaguchi (Japan)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 5 a</strong> : Initial Assessment of Urinary and Faecal Incontinence in Adult Male and Female Patients</td>
<td>331</td>
</tr>
<tr>
<td>D. Staskin (USA), C. Kelleher (U.K), K. Avery (U.K), R. Bosch (N.L), N. Cotterill (U.K), K. Coyne (USA), A. Emmanuel (U.K), M. Yoshida (Japan) Consultant : Z. Kopp (USA)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 5 B</strong> : Patient-Reported Outcome Assessment</td>
<td>363</td>
</tr>
<tr>
<td><strong>Committee 6</strong> : Dynamic Testing</td>
<td>413</td>
</tr>
<tr>
<td>G. Hosker (U.K), P. Rosier (The Netherlands), J. Gajewski (Canada), P. Sand (USA) Consultants : L. Szabo (Hungary), A. Capewell (U.K)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 7 A</strong> : Clinical neurophysiological Tests</td>
<td>523</td>
</tr>
<tr>
<td>D. Vodusek (Slovenia), G. Amarenco (France), S. Podnar (Slovenia)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 7 B</strong> : Imaging and other Investigations</td>
<td>541</td>
</tr>
<tr>
<td>A. Tubaro (Italy), W. Artibani (Italy), C. Bartram (U.K), J. DeLancey (USA), V. Khullar (U.K), M. Vierhout (The Netherlands) Consultants : M. De Gennaro (Italy), K. Kluivers (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 8</strong> : Pharmacological Treatment of Urinary Incontinence</td>
<td>631</td>
</tr>
<tr>
<td>Karl-Erik Andersson (USA), C. R Chappie (U.K), L. Cardozo (U.K), F. Cruz (Portugal), H. Hashim (U.K), M.C. Michel (The Netherlands), C. Tannenbaum (Canada), A.J. Wein (USA)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 9</strong> : Diagnosis and management of urinary incontinence in childhood</td>
<td>701</td>
</tr>
<tr>
<td>S. Tekgul (Turkey), R. JM Nijman (The Netherlands), P. Hoebeke (Belgium), D. Canning (USA), W. Bower (Hong-Kong), A. von Gontard (Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>Committee 10</strong> : Neurologic Urinary and Faecal Incontinence</td>
<td>793</td>
</tr>
<tr>
<td>J.J. Wyndaele (Belgium), A. Kovindha (Thailand), H. Madersbacher (Austria), P. Radziszewski (Poland), A. Ruffion (France), B. Schurch (Switzerland) Consultants : D. Castro (Spain), Y. Igawa (Japan), R. Sakakibara (Japan) Advisor : I. Perkash (USA)</td>
<td></td>
</tr>
</tbody>
</table>
Committee 11: Incontinence in the Frail Elderly
C.E. DuBeau (USA), G.A. Kuchel (USA), T. Johnson (USA), M.H. Palmer (USA), A. Wagg (U.K)

Committee 12: Adult Conservative Management
J. Hay Smith (New Zeland), B. Berghmans (The Nederlands), K. Burgio (USA), C. Dumoulin (Canada), S. Hagen (U.K), K. Moore (Canada), I. Nygaard (USA)
Consultant: J. N'dow (U.K)

Committee 13: Surgical Treatment of Urinary Incontinence in Men
S. Herschorn (Canada), H. Bruschini (Brazil), C. Comiter (USA), P. Grise (France), T. Hanus (Czech Republic), R. Kirschner-Hermanns (Germany)

Committee 14: Surgery for urinary incontinence in women
T. Smith (U.K), D. Chang (U.K), R. Dmochowski (USA), P. Hilton (U.K), C.G Nilsson (Finland), F.M Reid (U.K), E. Rovner (USA)

Committee 15: Surgery for pelvic organ prolapse
L. Brubaker (USA), C. Glazener (U.K), B. Jacquelin (France), C. Maher (Australia), A. Melgrem (USA), P. Norton (USA), N. Rajamaheswari (India), P. Von theobald (France)

Committee 16: Conservative and Pharmacological Management of Faecal Incontinence in Adults
C. Norton (U.K), W. Whitehead (USA), D. Z Bliss (USA), D. Harari (U.K), J. Lang (U.K)

Committee 17: Surgery for Faecal Incontinence
R.D. Madoff (USA), S. Laurberg (Denmark), K.E. Matzel (Germany), A.F. Mellgren (USA), T. Mimura (Japan), P.R. O’Connell (Ireland), M.G. Varma (USA)

Committee 18: Fistulas in the Developing World
D. De Ridder (Belgium), G. H. Badlani (USA), A. Browning (Ethiopia), P. Singh (India), I. Sombie (Burkina Faso), L. L. Wall (USA)

Committee 19: Bladder Pain Syndrome
P. Hanno (USA), A. Lin (Taiwan), J. Nordling (Denmark), L. Nyberg (USA), A. van Ophoven (Germany), T. Ueda (Japan)

Committee 20: Management Using Continence Products
A. Cottenden (U.K), D.Z.Bliss (USA), B. Buckley (Ireland), M. Fader (U.K), K. Getliffe (U.K), J. Paterson (Australia), R. Pieters (Belgium), M. Wilde (USA)

Committee 21: Continence Promotion, Education & Primary Prevention
D. K. Newman (USA), C. H. Ee (Singapore), D. Gordon (Australia), V. S. Srin (India), K. Williams (U.K) Consultants: B. Cahill (Australia), B. Gordon (USA), T. Griebling (USA), K. Nishimura (Japan) N. Norton (USA)

Committee 22: Economics of Urinary & Faecal Incontinence, and Prolapse
K. Moore (Australia), T. Wei Hu (USA), L. Subak (USA), T. Wagner (USA), M. Deutekom (The Netherlands)

Committee 23: Research
C. Payne (USA), J. Brown (USA), D. Castro (Spain), F. Daneshgari (USA), F. Haab (France), Y. Igawa (Japan), J. Kusek (USA), G. Rortveit (Norway), M-A Stothers (Canada), P. Van Kerreboreck (The Netherlands), P. Zimmern (USA)

Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence

Index